Abstract:e20535 Background: Postoperative or perioperative systematic chemotherapies (CTs) in patients with non-small cell lung cancer (NSCLC) have been widely accepted due to providing significant clinical benefits of patient survivals compared to the patients with surgical resections alone. In the pN2 NSCLC patients, the superiority of perioperative CTs to postoperative CTs remains controversial. The study was designed to compare treatment outcomes of the perioperative and postoperative CTs in the target population. Methods: The study data on the pN2 NSCLC patients who received curative radical resection from 2014 to 2017 were collected from the LinkDoc database to compare patient prognoses. The OS were measured by the Kaplan-Meier method and the Log-Rank test. Propensity score matching (PSM) method was implemented to reduce selection bias. Results: Of all the enrolled 766 patients, 688 (89.8%) patients were administered with postoperative CTs, and 78 (10.2%) patients with perioperative CTs. The medians of the follow-up durations in the patients with postoperative and perioperative chemotherapies plus surgeries were 12 months and 14 months, respectively. No significant OS difference in the patients with surgeries plus postoperative or perioperative chemotherapies was observed regardless of PSM within such short follow-up durations. In the subgroup with postoperative CTs, OS of the patients with adenocarcinoma was superior to that of the patients with squamous cell carcinomas (HR = 0.60, p < 0.01); the three-year OS of the patients with adenocarcinoma was found to be remarkably different from that of the patients with squamous cell carcinoma (68.9% vs 48.8%, P < 0.05). The most common complications were pleural effusion, pneumonia, and pneumothorax in the patients with postoperative CTs (5.8%,5.5%,4.2%) and perioperative CTs (6.4%,6.4%,3.8%). Conclusions: Our preliminary analyses showed that there was no significant OS difference in the pN2 NSCLC patients with perioperative and postoperative CTs plus surgeries due to the short follow-up duration. The patients will be followed up for observation of long-term patient survivals. Clinical trial information: ChiCTR1800014702.

Cost-minimization analysis of three chemotherapy schemes for non-small cell lung cancer

Evaluation on Pharmacoeconomics of NP versus GP for Advanced Nonsmall-cell Lung Cancer(NSCLC)

Supplementary Material For: A Cost-Effectiveness Analysis of Docetaxel Versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

A Cost-Effectiveness Analysis of Docetaxel Versus Pemetrexed in Second-Line Chemotherapy for Stage IIIb or IV Non-Small Cell Lung Cancer in China

Economic Analysis and Feasibility of Ambulatory Chemotherapy for Lung Cancer

Patient Preferences for Chemotherapy in the Treatment of Non-Small Cell Lung Cancer: A Multicenter Discrete Choice Experiment (DCE) Study in China

Comparison of Surgeries Plus Perioperative and Postoperative Chemotherapies in Chinese Pn2 Patients with Non-Small Cell Lung Cancer: A Real-World Observational Study.

Health Resource Utilization in Patients with Advanced Non-Small Cell Lung Cancer Receiving Chemotherapy in China

A Clinical Study of DP and GP in Treating Advanced Non-Small Cell Lung Cancer(nsclc)

Physician Preferences for Chemotherapy in the Treatment of Non-Small Cell Lung Cancer in China: Evidence from Multicentre Discrete Choice Experiments

Comparison of Cisplatin-Mitomycin-vinorelbine Versus Cisplatin-Mitomycin-vindesine Regimen for Treatment of Advanced Non-Small Cell Lung Cancer: a Report of 83 Patients

Comparison of Different Regimen in Treatment of Patients with Advanced Non-Small Cell Lung Cancer

Quantitative comparison of the efficacies and safety profiles of three first-line non-platinum chemotherapy regimens for advanced non-small cell lung cancer

Different Chemotherapeutic Scheme Plus Radiation for Inoperable Stage III Non-Small Cell Lung Cancer

Cost-Effectiveness Analysis of Camrelizumab Plus Chemotherapy Vs. Chemotherapy Alone As the First-Line Treatment in Patients with IIIB–IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Without EGFR and ALK Alteration from a Perspective of Health - Care System in China

Comparison of the Cost of 4 Kinds of Second-line Drug Treatment Regimes for Non-small Cell Lung Cancer

Real-World Cost-Effectiveness Analysis of Gemcitabine and Cisplatin Compared to Docetaxel and Cisplatin Plus Fluorouracil Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Clinical Observation of Chemotherapy with NP and GP Regimens on Advanced Non-Small Cell Lung Cancer Patients

Comparisons of two chemoradiotherapy regimens for locally advanced non-squamous and non-small cell lung cancer

Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China

The Cost Of Treating Advanced Non-Small Cell Lung Cancer: Estimates From The Chinese Experience